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Abstract
Crohn’s disease (CD) and ulcerative colitis (UC) are the two common forms of idiopathic inflammatory bowel disease (IBD). The aetiol-
ogy and pathogenesis of IBD are not yet known. Genetic predisposition has been suggested as playing a role in the improper immune 
response to commensal microbiota. The main link of IBD pathogenesis is an intestinal immune system disability after enteric infection, 
resulting in an uncontrolled and chronic inflammatory state. 
Recently, numerous studies have been focused on the role of proinflammatory cytokines as well as hormones of adipose tissue named 
adipokines in the pathogenesis of IBD. Adipokines have pro- and anti-inflammatory properties and can modulate the immune response. 
It has been shown that obesity is associated with systemic microinflammation. On the other hand, experimental studies have revealed 
a link between levels of some adipokines and the severity of inflammation in IBD independent of body mass. The fat deposits called ‘wrap-
ping’ or ‘creeping’ fat envelop the intestine, and adipokines produced by this tissue play an important role in the pathogenesis of IBD. 
The aim of this manuscript was to review the current literature concerning the role of adipokines in the pathogenesis of IBD. 
(Endokrynol Pol 2013; 64 (3): 226–231)
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Streszczenie 
Choroba Crona (CD) i wrzodziejące zapalenie jelit są najczęściej występującymi postaciami nieswoistych zapaleń jelit. Ich etiologia 
i patogeneza dotychczas nie zostały wyjaśnione. Sugeruje się, że przewlekły stan zapalny jelit jest wynikiem predyspozycji genetycznych 
i indywidualnej nadmiernej reakcji układu immunologicznego na antygeny fizjologicznej mikroflory jelitowej. Uważa się, że naruszenie 
równowagi jelitowego układu immunologicznego jest spowodowane infekcją jelitową, która prowadzi do zmian w składzie fizjologicz-
nej mikroflory jelitowej. Bierze się także pod uwagę takie czynniki, jak pochodzenie geograficzne i etniczne oraz styl życia. W ostatnich 
latach liczne badania oceniały rolę cytokin prozapalnych i hormonów tkanki tłuszczowej nazywanych adipokinami w patogenezie nie-
swoistych zapaleń jelit. Adipokiny wykazują zarówno pro-, jak i przeciw- zapalne działania i mogą uczestniczyć w regulacji odpowiedzi 
immunologicznej. Wykazano także, że otyłość wiąże się z przewlekłym układowym stanem zapalnym. Z drugiej strony wyniki badań 
eksperymentalnych ujawniły związek między stężeniem krążących adipokin a nasileniem procesu zapalnego w jelicie niezależnie od 
masy ciała. Wydaje się, że istotną rolę w wytwarzaniu adipokin uczestniczących w patogenezie nieswoistego zapalenia jelita odgrywa 
depozyt tłuszczu zlokalizowany w krezce jelita i bezpośrednio je otaczający.
Celem prezentowanej pracy był przegląd aktualnej literatury dotyczącej roli adipokin w patogenezie nieswoistych zapaleń jelit, takich 
jak choroba Crona i wrzodziejące zapalenie jelita grubego. (Endokrynol Pol 2013; 64 (3): 226–231)
Słowa kluczowe: leptyna, adiponektyna, rezystyna, wisfatyna, TNF-a, IL-6, choroba Crona, wrzodziejące zapalenie jelita grubego
Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are the 
two common forms of idiopathic inflammatory bowel 
disease (IBD). The aetiology and pathogenesis of both 
IBD forms are not yet known. It has been suggested 
that chronic inflammation of the bowel is the result of 
genetic predisposition and improper immune response 
to gut commensal microbiota [1]. The importance of 
genetic predisposition in the pathogenesis of IBD is 
confirmed by the results described in its higher preva-
lence in Ashkenazi Jews and first-degree relatives of 
patients diagnosed with IBD [2]. Moreover, at least 
nine distinct chromosomal regions loci variants related 
to IBD have been identified [3, 4]. Additionally, the role 
of lifestyle in the development of IBD has also been 
shown [5]. However, the main link of IBD pathogenesis 
seems to be disability of intestinal immune system after 
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enteric infection, resulting in changes of gut commen-
sal microbiota composition as well as an uncontrolled 
and chronic inflammatory state. So far no specific mi-
croorganism involved in the pathogenesis of IBD has 
been identified. Therefore, it has been hypothesised 
that disturbed gut microbiota composition rather than 
a specific pathogen play a role in the pathogenesis of 
IBD [6]. The additional known factors, modulating im-
mune system activation and affecting the development 
of IBD, include use of non-steroidal anti-inflammatory 
drugs [7], smoking [8], and recent appendectomy [9]. 
It should be emphasised that smoking is a risk factor 
for CD [10], while in UC it decreases the severity of 
inflammation [11, 12]. Recently, numerous studies have 
been focused on the role of proinflammatory cytokines 
as well as adipose tissue hormones (adipokines) in the 
pathogenesis of IBD. It has been shown that obesity 
per se is associated with systemic microinflammation, 
and disturbed circulating adipokines levels [13, 14]. Ad-
ditionally, the results of experimental studies revealed 
a link, independent of body mass, between plasma 
levels of adipokines and severity of colitis [15]. In rats, 
increased mesenteric fat deposit has been observed 
during experimental colitis, despite a reduction of 
body mass and enhanced release of TNF-a and leptin 
by mesenteric and perinodal adipose tissue [30]. Thus, 
the adipokines produced by these fat deposits called 
‘wrapping’ or ‘creeping’ fat enveloping the intestine 
seem to play an important role in the pathogenesis of 
IBD [15, 16].
This study reviews the literature concerning the 
role of adipokines in the pathogenesis of IBD such as 
Crohn’s disease and ulcerative colitis. 
Leptin 
Leptin is a 16kDa polypeptide hormone produced 
predominantly by the subcutaneous white adipose 
tissue (sWAT) [17]. The circulating leptin level is pro-
portional to body mass index (BMI) and fat mass [18]. 
Leptin is known as a peripheral signal of satiety [9, 19, 
20]. Its other biological activities include regulation 
of hematopoietic, angiogenesis, reproduction and 
hypothalamic-pituitary-adrenal axis activation [20–23]. 
Moreover, leptin has proinflammatory properties. 
Increased circulating leptin level has been observed 
in infectious and inflammatory diseases [24, 25]. This 
adipokine stimulates TNF-a and IL-6 production, in-
creases iNOS activity and the secretion of nitric oxide 
(NO), activates synthesis of leukotriene by monocytes 
and macrophages, and modulates function of CD4+ T 
lymphocytes [18, 26]. This suggests that leptin plays an 
important role in immunity, influencing the function of 
immune cells by the regulation of cytokine production 
and polarising T helper cells toward Th1 (long isoform 
of leptin receptor is expressed on T lymphocytes) [24].
Experimental studies have revealed that leptin 
modulates intestinal inflammation [27, 28]. It has been 
shown that leptin-deficient mice are protected from 
inflammation in some models of IBD [29], whereas, in 
a rat experimental model of intestinal inflammation, 
elevated plasma leptin level was observed, regardless 
of inflammation severity and nutritional status [30]. 
Overexpression of leptin mRNA in mesenteric visceral 
adipose tissue (mWAT) has also been found in IBD 
subjects, [31, 32], contrary to the suppression of leptin 
secretion by cultured differentiated human adipocytes 
in chronic inflammatory conditions [32]. The response 
of colonic cells to inflammation includes leptin release 
into the gut lumen which exacerbates the epithelial 
damage and neutrophil infiltration. Therefore, luminal 
concentrations of leptin are significantly higher in pa-
tients with active IBD than in normal colonic luminal 
fluid [33]. The studies exploring plasma leptin level in 
IBD have revealed conflicting results. Its levels have 
been found to be increased [34], unaffected [35], and 
even decreased [36]. Additionally, infiximab therapy 
in patients diagnosed with IBD increases circulating 
leptin level [37]. Larger studies in humans are necessary 
to clarify the role of leptin in the pathogenesis of IBD. 
Potentially, increased circulating leptin, as well as 
other proinflammatory cytokines, may increase satiety 
and decrease food intake in IBD subjects, leading to 
the development of malnutrition. On the other hand, 
a high leptin level may improve nutrient absorption. 
It has been shown that leptin may stimulate nutrient 
absorption by long isoform of its receptor (OB-Rb) 
localised in brush border or basolateral membrane of 
enterocytes [38].
An important limitation of the performed studies, 
and perhaps the cause of conflicting results, is the lack 
of nutritional status assessment in IBD subjects. There-
fore, more detailed studies are necessary to clarify the 
potential role of leptin in the pathogenesis of IBD. 
Adiponectin
Adiponectin is a 244-amino acid protein, produced 
predominantly by WAT. The monomeric form (30kDa) 
as well as oligomeric complexes - low molecular weight 
(LMW) trimers, middle molecular weight (MMW) hex-
amers, and high molecular weight (HMW) multimers, 
of adiponectin seem to be secreted only by adipocytes. 
It has been suggested that HMW is the most important 
biologically active adiponectin form [39]. 
Low plasma adiponectin level has been shown in 
obesity, type 2 diabetes, dyslipidemia and hyperten-
sion [40–42], while increased adiponectin levels have 
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been observed in patients with anorexia nervosa and 
in fasting healthy subjects [43].
Adiponectin has anti-inflammatory properties. It 
reduces the release of proinflammatory cytokines such 
as TNF-a and IL-6 and induces secretion of anti-inflam-
matory factors (IL-10 and IL-1-receptor antagonist), by 
macrophages and lymphocytes [44, 45]. Moreover, this 
adipokine inhibits expression of adhesion molecules 
(vascular cell adhesion molecule-1, E-selectin, intercel-
lular adhesion molecule-1 and IL-8) in endothelial cells 
[46–48]. However, some investigators suggest that the 
HMV adiponectin and its globular domain have proin-
flammatory properties and participate in NFkB activa-
tion [49]. Furthermore, elevated plasma adiponectin 
level has been found in autoimmune diseases such as 
rheumatoid arthritis [50]. 
The dual role of adiponectin in IBD has also been 
shown in experimental studies. Adiponectin-knockout 
mice (APN-KO) were developing much more severe 
colitis, that was attenuated by supplementation of 
adiponectin, probably by the inhibition of LPS-induced 
IL-8 production in intestinal epithelial cells [51]. On the 
other hand, adiponectin-deficient mice were protected 
from chemically induced colitis, and the administration 
of adiponectin restored inflammation by the increase of 
proinflammatory cytokines production and inhibition 
of growth factor activity [52].
In humans, tissue concentration of adiponectin in 
hypertrophic mesenteric adipose tissue and its release 
were significantly higher in subjects with CD than 
UC [53]. However, the results of studies assessing 
the circulating adiponectin level in IBD subjects are 
inconclusive. Both elevated [36] and decreased [35] adi-
ponectin levels in IBD have been observed. Moreover, 
a higher adiponectin level in UC and lower in CD in 
women, but not in men, has been found [54]. There-
fore, gender-related differences in adiponectin action 
in IBD have been suggested. Moreover, some authors 
have suggested that circulating adiponectin may be a 
risk factor for the occurrence of glucocorticoid-related 
side effects in children and adolescents with IBD [55].
To clarify the role of adiponectin in the pathogenesis 
of IBD, further experimental and clinical studies are nec-
essary, especially concerning the association between 
plasma adiponectin levels, IBD and nutritional status 
as well as fat deposits. 
Resistin 
Resistin is a 12.5-kDa member of the cysteine-rich 
proteins family, cloned in 2001 as a thiazolidinedione-
regulated cytokine expressed in rodent adipose tissue. It 
was initially described as an adipocyte-derived media-
tor of hepatic insulin resistance [56]. When translating 
the role of resistin from animals to humans, the inter-
species differences have to be taken into consideration. 
The main source of circulating resistin in animals and 
in humans is different. In animals, resistin is mainly 
produced by visceral adipocytes [57], while in humans 
it is by mononuclear cells [58]. Human visceral adipose 
tissue (predominantly macrophages) produces only 
a small part of circulating resistin [59]. Additionally, 
mouse and human resistin demonstrates only 64.4% 
mRNA sequence and 59% amino acids homology [60]. 
This suggests that the physiological function of resistin 
is different in animals and humans [61]. Numerous 
studies have revealed that in humans resistin has pro-
inflammatory properties. This protein activates NF-kB 
signalling pathway and induces production of IL-6, 
IL-1b and TNF-a by monocytes [57, 61]. Other potential 
but little known functions of resistin are regulation of 
metabolic processes and adipogenesis [62]. The proin-
flammatory action of resistin has been confirmed by 
clinical studies that have revealed the increased level of 
this protein in rheumatoid arthritis and IBD [63-66]. It 
has also been shown that resistin production in mWAT 
is significantly greater in CD than in subjects with colon 
cancer. Additionally, plasma resistin level in CD and UC 
patients was increased, independently of the disease 
severity [36]. Additionally, the increased circulating 
resistin level in subjects with active IBD but not dur-
ing remission was found [35]. This suggests the role of 
resistin in the inflammation process in IBD.
Visfatin 
Visfatin is an adipokine originally identified in visceral 
adipose tissue. The structure of visfatin is identical to 
pre-B-cell colony-enhancing factor (PBEF). An experi-
mental study revealed the insulin-mimetic properties 
of visfatin. It was shown that in vitro visfatin enhances 
glucose uptake by adipocytes and myocytes and inhibits 
glucose release by hepatocytes [47]. We have recently 
described a higher circulating visfatin level in obese 
compared to normal weight women [67]. WAT-derived 
macrophages and stromal vasculature, rather than adi-
pocytes, are the main source of circulating visfatin [68, 
69]. It has been suggested that visfatin is a proinflam-
matory marker of adipose tissue resident macrophages. 
Numerous studies have confirmed this hypothesis. 
Density of resident macrophages in adipose tissue in 
obese subjects has been shown to be increased. Moreo-
ver, both plasma visfatin and TNF-a levels increase with 
BMI, and correlate with each other [70].
Visfatin stimulates production of matrix-metal-
loproteinase-9 by monocytes and proinflammatory 
cytokines, such as TNF-a, IL-6 and IL-8 by peripheral 
blood mononuclear cells [71, 72]. Increased expression 
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of visfatin in peripheral blood mononuclear cells has 
also been shown in rheumatoid arthritis [64], acute lung 
injury [73] and psoriasis [74].
Recently elevated plasma visfatin level has also 
been observed in subjects diagnosed with IBD. In CD 
subjects, increased circulating visfatin concentration 
was observed independent of the disease severity, while 
in UC subjects visfatin level was related to severity of 
inflammation. The expression of visfatin was localised 
to macrophages, epithelial and dendritic cells within 
mucosa membrane of IBD patients [75]. 
Additionally, visfatin has been found to be a causa-
tive factor of decreased bone mass density (BMD) in 
IBD subjects [76]. 
Thus, visfatin seems to be a link in the pathogenesis 
of IBD and may play a role in the development of IBD 
complications such as secondary osteoporosis. 
Interleukin 6 (IL-6)
Interleukin 6 is a cytokine produced by numerous 
cells, including fibroblasts, monocytes, macrophages, 
endothelial cells and adipocytes. Adipose tissue, es-
pecially visceral fat, is a significant source of circulat-
ing IL-6 (30%) [77]. In obese subjects, an increasing, 
proportional to BMI, circulating IL-6 level has been 
shown [78–80]. 
Experimental studies have revealed that IL-6 plays 
an important role in the development of insulin re-
sistance by the inducing the suppression of cytokine 
signalling-3 pathway [81] and stimulating C-reactive 
protein (CRP) production by hepatocytes [82]. Ad-
ditionally, IL-6 stimulates hematopoiesis, maturation 
of B-cells, T-cell growth, as well as differentiation of 
neurons [82]. 
Increased concentration of IL-6 in samples col-
lected from both peripheral and mesenteric veins in 
subjects with active CD, but not with UC, has been 
shown. It has been suggested that peripheral blood 
mononuclear cells, endothelial cells and fibroblasts 
are the main source of circulating IL-6 in CD subjects 
[83]. In other studies, increased IL-6 level and its 
relation to disease severity in CD subjects has been 
found [84, 85]. Therefore, potentially, IL-6 could be 
a useful marker in the differentiation of CD and UC, 
and clinical monitoring of CD severity [86, 87]. How-
ever, contradictory results have also been published, 
showing that secretion of IL-6 in mesenteric fat tissue 
did not differ in subjects with CD, colon cancer and 
diverticulitis [53, 65]. Finally, large clinical trials have 
not confirmed the usefulness of IL-6 assessment in 
CD [88]. Therefore, it seems that elevated circulating 
IL-6 level may reflect systemic chronic inflammation 
accompanying IBD.
Tumour necrosis factor-alpha (TNF-a)
Tumour necrosis factor-a is a proinflammatory cytokine 
produced mainly by macrophages, lymphocytes and 
in low quantities by human adipocytes [89]. TNF-a 
directly and indirectly participates in the inflamma-
tory process through recruitment and activation of 
inflammatory cells. TNF-a interferes also with other 
cytokines in inflammation and induces catabolism [90], 
by stimulation of lipoprotein lipase activity and insulin 
resistance development [91]. 
Taking into account everything described above, 
the question arises concerning the participation of 
adipocyte-derived TNF-a in a chronic inflammation 
disease, such as IBD. Desreumaux et al. [92] revealed 
especially elevated secretion of TNF-a from mesenteric 
adipocytes. It has been suggested that TNF-a synthesis 
by mesentery adipose tissue is causally linked to the 
specific location of mucosal ulcerations [93]. Moreover, 
Gambero et al. [16] in experimental colitis observed 
its increased production in mesenteric, especially by 
perinodal, adipose tissue, and this may explain high 
basal mesenteric lipolytic activity. Elevated TNF-a 
production by intestinal mucosa in CD patients has 
also been shown [94]. Tumour necrosis factor-a acti-
vates endothelial cells, induces chemokines secretion 
and recruits neutrophils in gut mucosa [95]. In Crohn’s 
disease, elevated TNF-a level increases leptin mRNA 
expression in adipocytes [96, 97]. Kohut et al. [85] sug-
gested that circulating TNF-a level may be a marker 
distinguishing patients with and without Crohn’s dis-
ease. The important role of TNF-a in the pathogenesis 
of CD is confirmed by the effectiveness of therapy with 
anti-TNF-a drugs in this disease [98].
An increased TNF-a level in the plasma, colonic tis-
sue and stool of UC subjects has also been observed [99]. 
However, no studies have assessed TNF-a production 
by intestinal mucosa and perinodal mesenteric adipose 
tissue in UC patients. 
Is obesity a risk factor for inflammatory 
bowel diseases? 
Crohn’s disease and ulcerative colitis generally occur 
more frequently in obese than in normal weight and 
underweight subjects. Therefore, some researchers 
have hypothesised that obesity may participate in the 
pathogenesis of IBD and influence its severity [100, 
101]. The data obtained by Mendall et al. [101] revealed 
a higher frequency of obesity in patients with CD than 
ulcerative colitis and healthy controls. A correlation be-
tween BMI and risk for CD development has also been 
shown. Further studies have revealed that the activity of 
CD is more severe in obese than in non-obese subjects 
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[100]. Contradictory data concerning the frequency of 
obesity in IBD was obtained in a paediatric population. 
In children newly-diagnosed with IBD, the prevalence 
of overweight and obesity was higher in UC than CD 
subjects (30% v. 20%) [102, 103]. However, the associa-
tion between obesity and severity of the disease (higher 
rates of IBD-related surgery interventions) was found 
only in CD children [102]. 
The results of the few studies published so far, as 
well as the above described data, suggest that adi-
pokines are the link between obesity and IBD. 
Summary 
Disturbances in hormonal function of adipose tissue 
in obesity seem to modulate immune activity and 
participate in the pathogenesis as well as the course of 
IBD. However, further studies are necessary to clarify 
the role of visceral and mesenteric adipose tissue and 
more precisely describe the links between obesity and 
IBD development.
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